tmem178b Antibody

What is TMEM178B and what is its biological significance?

TMEM178B (Transmembrane Protein 178B) is a membrane-localized protein belonging to the TMEM178 protein family. In humans, the canonical protein consists of 294 amino acid residues with a molecular weight of approximately 33.4 kDa. As a transmembrane protein, its subcellular localization is in the cellular membrane and it undergoes post-translational modifications, including glycosylation. TMEM178B gene orthologs have been identified across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken, suggesting evolutionarily conserved functions . While TMEM178B itself remains less characterized, research on the related TMEM178A has revealed important roles in regulating inflammatory responses through modulation of calcium signaling pathways and inhibition of NLRP3 inflammasome activation, suggesting potential similar functions for TMEM178B .

What types of TMEM178B antibodies are currently available for research?

Several types of TMEM178B antibodies are commercially available for research applications, varying in host species, reactivity, and validated applications:

These antibodies provide researchers with options for studying TMEM178B across different experimental contexts and model organisms, with validated applications primarily focused on immunohistochemistry (IHC), Western blotting (WB), and enzyme-linked immunosorbent assay (ELISA) .

How is TMEM178B structurally and functionally related to TMEM178A?

TMEM178B shares structural similarity with TMEM178A as a member of the same protein family, though their precise functional relationship requires further investigation. Research on TMEM178A has established its role as a negative regulator of inflammatory responses, particularly in regulating IL-1β production through inhibition of store-operated calcium entry (SOCE)-dependent NLRP3 inflammasome activation . TMEM178A has also been shown to function as a negative regulator of osteoclast differentiation by controlling NFATc1 induction via calcium signaling modulation . Given their structural homology, TMEM178B may perform related functions in calcium signaling and inflammatory regulation, potentially in different tissue contexts or signaling pathways. The similar structural features of these proteins suggest overlapping but possibly distinct functional roles that warrant comparative investigation using specific antibodies.

What are the recommended applications for TMEM178B antibodies?

TMEM178B antibodies are validated for several key immunological techniques that enable different aspects of protein analysis:

For Western blotting, TMEM178B antibodies can detect the protein in cell or tissue lysates, revealing its expression levels and molecular weight. This technique is particularly valuable for confirming antibody specificity and tracking protein expression changes under different experimental conditions. Several available antibodies from suppliers like MyBioSource.com and CUSABIO are specifically validated for this application .

For immunohistochemistry (IHC), TMEM178B antibodies enable visualization of protein distribution in tissue sections, providing critical information about cellular and subcellular localization. The Novus Biologicals antibody is specifically validated for IHC applications, including paraffin-embedded tissues (IHC-p) .

For ELISA applications, TMEM178B antibodies permit quantitative measurement of the protein in solution, allowing researchers to detect and quantify TMEM178B in complex biological samples. Multiple suppliers offer antibodies validated for this technique, including those with zebrafish reactivity .

When designing experiments, researchers should carefully match their selected antibody with their intended application and target species, as different antibodies have specific validated uses and species reactivity profiles.

What is the typical expression pattern of TMEM178B in different tissues and cell types?

While comprehensive TMEM178B expression mapping continues to evolve, current knowledge suggests distinct patterns that inform experimental design. TMEM178B is primarily localized to cellular membranes, consistent with its identity as a transmembrane protein . Based on research on the related TMEM178A, significant expression in immune cells, particularly monocytes and macrophages, is likely, especially in inflammatory contexts .

The presence of TMEM178B orthologs across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken suggests evolutionarily conserved functions, though expression patterns may vary between species . Expression in osteoclasts is also likely, given TMEM178A's established role in osteoclast differentiation through NFATc1 signaling .

For definitive tissue expression analysis, researchers should combine immunohistochemistry using validated TMEM178B antibodies with mRNA expression data from publicly available RNA-seq datasets. This dual approach helps confirm protein presence while accounting for potential post-transcriptional regulation.

How can I validate the specificity of a TMEM178B antibody for my experimental system?

Validating antibody specificity is essential for generating reliable research data. For TMEM178B antibodies, implement a multi-faceted validation approach:

First, employ positive and negative controls. Use tissues or cell lines known to express TMEM178B as positive controls, while TMEM178B knockout models or cells where the protein is not expressed serve as crucial negative controls. Western blot analysis should verify a single band at the expected molecular weight (approximately 33.4 kDa for human TMEM178B) , with band disappearance in knockout or knockdown samples.

Consider blocking peptide competition experiments, where pre-incubating the antibody with excess purified antigen peptide should eliminate specific staining. Multiple antibody validation using antibodies recognizing different TMEM178B epitopes should yield consistent results if all are specific.

RNA-protein correlation analysis comparing protein detection with mRNA expression data provides additional validation, as consistent correlation supports antibody specificity. For definitive validation, mass spectrometry confirmation of protein identity in immunoprecipitated samples represents the gold standard.

For cross-species studies, verify the antibody's reactivity to the target species has been validated, as epitope conservation may vary between orthologs. These rigorous validation approaches help distinguish specific signal from artifacts, ensuring research reliability.

What sample preparation methods are optimal for detecting TMEM178B?

Optimal detection of TMEM178B requires specific sample preparation approaches that account for its membrane localization and post-translational modifications. For protein extraction, use RIPA or NP-40 based lysis buffers containing appropriate detergents to effectively solubilize membrane proteins. Always include protease inhibitor cocktails to prevent degradation and phosphatase inhibitors if studying phosphorylation status.

Consider the impact of post-translational modifications, particularly glycosylation, which TMEM178B is known to undergo . For some applications, treating a portion of your samples with deglycosylating enzymes like PNGase F may help identify the core protein band versus modified forms.

For immunohistochemistry, optimize fixation methods to preserve membrane protein epitopes. Formalin fixation followed by antigen retrieval is typically effective, though membrane proteins may require specific retrieval methods such as heat-induced epitope retrieval with citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0).

For flow cytometry applications, gentle cell dissociation methods help preserve surface epitopes. If targeting intracellular domains, optimize permeabilization conditions using reagents like saponin or Triton X-100 at appropriate concentrations.

When preparing samples for immunoprecipitation, use non-denaturing detergents at concentrations that maintain protein-protein interactions while effectively solubilizing membrane-bound TMEM178B. These specialized preparation approaches enhance detection sensitivity and specificity for TMEM178B across different experimental applications.

How can I effectively use TMEM178B antibodies to study its role in inflammatory signaling pathways?

Given that the related TMEM178A negatively regulates inflammatory responses through inhibition of NLRP3 inflammasome activation , similar approaches can be applied to investigate TMEM178B's potential role in inflammation. Begin with co-immunoprecipitation studies using TMEM178B antibodies to identify interaction partners, followed by mass spectrometry analysis. This approach can reveal connections to inflammatory signaling components and should include appropriate controls to distinguish specific from non-specific interactions.

For mechanistic studies, combine TMEM178B antibody staining with calcium imaging techniques, as calcium signaling is central to inflammasome regulation. Correlate TMEM178B expression levels with calcium flux measurements in wild-type versus knockout/knockdown cells to establish functional relationships. Monitor inflammasome activation by using anti-TMEM178B antibodies alongside markers of inflammasome assembly, such as ASC speck formation and NLRP3 oligomerization, quantifying their co-localization through confocal microscopy.

Critically, analyze cytokine production by correlating TMEM178B expression (detected by immunoblotting) with IL-1β production in stimulated macrophages or monocytes. This approach can determine if TMEM178B expression levels inversely correlate with inflammatory cytokine production similar to TMEM178A . Research has shown that Tmem178-deficient macrophages release increased levels of IL-1β following NLRP3 inflammasome activation, suggesting a negative regulatory function .

Finally, conduct translocation studies to monitor changes in TMEM178B subcellular localization during inflammatory activation using subcellular fractionation and immunoblotting or live-cell imaging with fluorescently tagged antibodies. These approaches will elucidate whether TMEM178B, like TMEM178A, functions as a negative regulator of inflammasome activation and inflammatory cytokine production.

How does post-translational modification affect TMEM178B detection with antibodies?

TMEM178B undergoes post-translational modifications, particularly glycosylation , which significantly impacts antibody detection across different applications. Glycosylation can mask antibody epitopes, especially for antibodies targeting regions containing N-glycosylation sites. To overcome this challenge, consider using antibodies targeting different epitopes if glycosylation interferes with detection.

For Western blot applications, glycosylation increases the apparent molecular weight on SDS-PAGE, potentially causing the canonical 33.4 kDa TMEM178B to appear larger . To distinguish between glycosylated forms, perform enzymatic deglycosylation using PNGase F or Endoglycosidase H prior to SDS-PAGE and compare with untreated samples. This comparative approach reveals the extent of glycosylation and helps identify the core protein.

Different tissue sources may exhibit variable banding patterns due to tissue-specific glycosylation profiles. When analyzing samples from multiple tissues or species, these differences must be accounted for in data interpretation. Additionally, if TMEM178B undergoes phosphorylation (as many signaling proteins do), phosphatase treatment may affect antibody recognition, and phospho-specific antibodies may be required to study activation-dependent phosphorylation events.

For detecting native protein in applications like immunoprecipitation or flow cytometry, consider that post-translational modifications may affect conformational epitopes differently than linear epitopes recognized in denatured Western blot samples. Understanding these modification-dependent detection variables is crucial for accurate interpretation of experimental results, particularly when comparing TMEM178B expression across different physiological or pathological conditions.

What strategies can be employed to study the differential functions of TMEM178B versus TMEM178A?

Distinguishing the functions of these related proteins requires specialized research strategies. Begin with isoform-specific knockdown/knockout approaches using siRNAs or CRISPR guides targeting unique regions of each gene. Validate specificity by measuring mRNA and protein levels of both isoforms after knockdown and compare phenotypic effects of individual versus combined knockdown to identify unique and overlapping functions.

Antibody selection is critical - use antibodies raised against non-conserved regions of TMEM178A and TMEM178B to ensure specificity. Validate these antibodies in cells expressing only one isoform to confirm they don't cross-react. For comprehensive expression analysis, compare tissue and cellular distribution patterns using specific antibodies and analyze public RNA-seq datasets for differential expression patterns.

Conduct structure-function studies by identifying unique structural domains or motifs in each protein. Create domain-specific deletion mutants to identify regions responsible for specific functions and use chimeric proteins combining domains from both proteins to determine functional regions. This approach is particularly relevant for studying their potentially different roles in calcium signaling and inflammatory regulation.

For interactome mapping, perform immunoprecipitation with specific antibodies followed by mass spectrometry to compare interaction partners of TMEM178A versus TMEM178B. Validate key interactions through reciprocal co-immunoprecipitation. Given TMEM178A's established role in calcium signaling , perform comparative calcium signaling analysis to study the effects of each protein on store-operated calcium entry and determine if they interact with different components of the calcium signaling machinery.

These complementary approaches will help establish the unique functions of TMEM178B while clarifying its relationship to the better-characterized TMEM178A, potentially revealing specialized roles in different tissues or cellular contexts.

How can TMEM178B antibodies be used to investigate its potential role in calcium signaling?

Given TMEM178A's established role in calcium signaling , similar methodologies can be applied to investigate TMEM178B's potential involvement in these pathways. Begin with subcellular localization studies using co-immunostaining with organelle markers (ER, Golgi, plasma membrane) and calcium-handling proteins like STIM1 and Orai1. Perform fractionation followed by immunoblotting to determine membrane distribution and co-localization with calcium channels and calcium-sensing proteins.

Integrate TMEM178B immunostaining with calcium imaging techniques to establish direct correlations between protein localization and calcium flux. Employ real-time analysis of TMEM178B localization during calcium signaling events, particularly focusing on store-operated calcium entry (SOCE), a process that TMEM178A has been shown to regulate . Manipulate TMEM178B expression through overexpression or knockdown approaches and measure resulting changes in calcium signaling parameters.

For protein interaction studies, use TMEM178B antibodies for immunoprecipitation followed by analysis of calcium handling proteins or employ proximity ligation assays with STIM1, Orai1, and other SOCE components. Analyze how these interactions change dynamically during calcium store depletion and refilling, and compare with TMEM178A interaction patterns.

Conduct functional calcium signaling assays by measuring SOCE in cells with TMEM178B knockdown or overexpression and analyze calcium-dependent transcriptional responses, particularly NFAT activation, which has been linked to TMEM178A function . Study ER calcium content and release kinetics to determine if TMEM178B influences calcium store management.

These approaches will help establish whether TMEM178B, like its family member TMEM178A, plays a significant role in regulating calcium homeostasis, potentially revealing new therapeutic targets for disorders involving calcium signaling dysregulation.

What are the optimal protocols for using TMEM178B antibodies in Western blot applications?

For optimal Western blot detection of TMEM178B, implement a specialized protocol that accounts for its membrane localization and post-translational modifications. For sample preparation, extract proteins using RIPA or NP-40 based buffers containing appropriate detergents to effectively solubilize membrane proteins. Include a complete protease inhibitor cocktail to prevent degradation. For glycosylated TMEM178B, consider treating a portion of your sample with PNGase F to observe migration shifts that identify glycoforms.

When preparing samples for loading, heat at 70°C instead of boiling to prevent aggregation of membrane proteins, which can occur with transmembrane proteins like TMEM178B. Use 10-12% polyacrylamide gels for optimal resolution around the 33.4 kDa range expected for human TMEM178B , and include appropriate positive controls from cells known to express the protein.

For transmembrane proteins, wet transfer typically yields better results than semi-dry transfer. Use PVDF membranes rather than nitrocellulose for improved retention of hydrophobic proteins, and consider transfer buffers containing 10-20% methanol to enhance transfer efficiency.

When blocking membranes, test both 5% non-fat milk and BSA in TBS-T to determine which provides optimal signal-to-noise ratio. Dilute primary antibodies according to manufacturer recommendations (typically 1:500 to 1:2000) and incubate overnight at 4°C with gentle agitation. For detection, high-sensitivity ECL substrates are recommended if TMEM178B expression is low in your samples.

When troubleshooting, high background can be addressed by increasing blocking time or changing blocking reagent. If multiple bands appear, evaluate whether these represent glycoforms, dimers, or non-specific binding by comparing with deglycosylated samples. These optimized techniques will help ensure specific and sensitive detection of TMEM178B in Western blotting applications.

How can TMEM178B antibodies be effectively used in immunohistochemistry for tissue localization studies?

For successful immunohistochemical detection of TMEM178B, implement a carefully optimized protocol that preserves membrane protein epitopes. Begin with proper tissue preparation by fixing tissues in 10% neutral buffered formalin for 24-48 hours. For bone tissues, which may be of particular interest given TMEM178A's role in osteoclasts , use appropriate decalcification methods that preserve antigenicity, such as EDTA-based decalcifiers rather than strong acids.

Antigen retrieval optimization is critical for membrane proteins like TMEM178B. Test multiple methods including heat-induced epitope retrieval using citrate buffer (pH 6.0), Tris-EDTA buffer (pH 9.0), and enzymatic retrieval using proteinase K. For membrane proteins, heat-induced methods typically provide better results, but empirical testing is essential for each tissue type.

For blocking and antibody incubation, block endogenous peroxidase activity with 3% hydrogen peroxide, followed by blocking non-specific binding with serum-free protein block or serum matching the secondary antibody host. Dilute the primary antibody according to manufacturer recommendations - the Novus Biologicals antibody is specifically validated for IHC applications . Incubate at 4°C overnight in a humidified chamber for optimal antibody binding.

Controls are essential for interpretation: include positive control tissues based on known expression patterns, use isotype controls to identify non-specific binding, include a negative control by omitting primary antibody, and consider peptide competition controls for specificity verification.

For image acquisition and analysis, capture images using consistent exposure settings and perform quantitative analysis using appropriate software. If conducting comparative studies, process and stain all samples simultaneously to minimize technical variability. These methodological considerations will help researchers achieve specific and informative immunohistochemical staining of TMEM178B in tissue sections.

What approaches are recommended for using TMEM178B antibodies in flow cytometry?

Optimizing flow cytometry protocols for TMEM178B detection requires specific considerations due to its membrane localization and expression characteristics. For sample preparation, ensure single-cell suspensions with minimal cell debris. When working with blood samples, use RBC lysis buffers that preserve membrane protein epitopes, and for bone marrow-derived cells that may express TMEM178B, employ gentle dissociation methods to prevent epitope degradation.

Fixation and permeabilization approaches depend on epitope location. If TMEM178B epitopes are intracellular or within transmembrane regions, fix cells with 2-4% paraformaldehyde and test different permeabilization reagents including saponin, Triton X-100, and methanol to determine optimal conditions. If targeting extracellular epitopes, stain with antibodies before fixation to prevent epitope masking.

When selecting antibodies, prioritize those with flow cytometry validation data. Unconjugated antibodies require fluorophore-conjugated secondary antibodies, while directly conjugated antibodies simplify multicolor panels. Validate specificity using knockout or knockdown controls whenever possible.

For staining protocol optimization, titrate antibody concentrations to determine the optimal signal-to-noise ratio. When working with immune cells, include Fc receptor blocking reagents to prevent non-specific binding. For multicolor panels, include appropriate compensation controls and use viability dyes to exclude dead cells, which can bind antibodies non-specifically.

In data analysis, use fluorescence minus one (FMO) controls to set positive gates accurately. Analyze TMEM178B expression as mean fluorescence intensity rather than percent positive cells to capture expression level variations within populations. Given that TMEM178A expression changes during cell activation , standardize stimulation protocols when studying TMEM178B in activated cells and compare expression between inflammatory and steady-state conditions. These specialized approaches will enable accurate flow cytometric analysis of TMEM178B expression.

What are the key considerations for using TMEM178B antibodies in immunoprecipitation studies?

Immunoprecipitation (IP) of TMEM178B requires specific methodological considerations to account for its transmembrane nature. When selecting antibodies, recognize that not all antibodies suitable for Western blot work effectively for IP. Check manufacturer validation data specifically for IP applications. Consider that monoclonal antibodies may offer higher specificity but might recognize only a single epitope, while polyclonal antibodies may provide better precipitation efficiency by binding multiple epitopes.

Lysis buffer optimization is critical for membrane proteins like TMEM178B. Use buffers containing non-denaturing detergents such as NP-40, Triton X-100, or digitonin at concentrations that maintain protein-protein interactions while effectively solubilizing membrane proteins. Include protease and phosphatase inhibitors to preserve protein integrity and interaction status. For studying weak interactions, consider chemical crosslinking before lysis.

Implement a rigorous IP protocol that includes pre-clearing lysates with protein A/G beads to reduce non-specific binding. Use 2-5 μg antibody per mg of total protein and allow sufficient binding time (4 hours to overnight) at 4°C. Perform multiple gentle washes to remove non-specific binders while preserving true interactions. Consider elution under non-denaturing conditions if co-IP partners will be analyzed functionally.

Controls are essential for interpretation: include IgG control from the same species as the antibody, use lysate from TMEM178B-knockdown cells as a negative control, and include input sample (pre-IP lysate) for comparison. For verification of identified interactions, employ multiple methods including reverse IP (immunoprecipitating with antibodies against suspected interaction partners), proximity ligation assay for in situ detection of protein-protein interactions, and mass spectrometry analysis of co-precipitated proteins.

Given TMEM178B's membrane localization, consider using membrane fractionation before IP to enrich for relevant compartments and interaction partners. These specialized approaches will facilitate successful immunoprecipitation of TMEM178B and identification of its physiologically relevant interaction network.

What are common issues encountered when using TMEM178B antibodies and how can they be resolved?

Researchers working with TMEM178B antibodies may encounter several technical challenges across different applications. One frequent issue is the absence of signal in Western blots, which may result from low expression levels, epitope masking by post-translational modifications (particularly glycosylation), denaturation-sensitive epitopes, or inefficient transfer of this hydrophobic membrane protein. To address these issues, consider enriching your sample through immunoprecipitation, treating with deglycosylating enzymes like PNGase F, reducing sample heating time or temperature, and optimizing transfer conditions specifically for membrane proteins.

Multiple bands in Western blots represent another common challenge, potentially resulting from glycosylation variants, proteolytic degradation, non-specific binding, or protein aggregation. Compare with deglycosylated samples to identify glycoforms, use fresh samples with protease inhibitors to minimize degradation, and optimize blocking conditions to reduce non-specific binding. Testing with TMEM178B-depleted samples can help identify which bands represent specific signal.

For immunohistochemical applications, high background staining may result from insufficient blocking, secondary antibody cross-reactivity, or endogenous peroxidase activity. Extend blocking time or try different blocking reagents, use secondary antibodies raised specifically against host species IgG (Fc-specific), and ensure thorough quenching of endogenous peroxidase activity. Titrating primary antibody concentration can also significantly improve signal-to-noise ratio.

When performing immunoprecipitation, poor efficiency may result from inefficient antibody binding, inadequate protein solubilization, binding competition from endogenous proteins, or weak antibody-bead interaction. Increase antibody amount or incubation time, optimize detergent type and concentration for this membrane protein, thoroughly pre-clear lysates, and consider direct antibody conjugation to beads for improved capture efficiency.

Inconsistent results between experiments often stem from antibody batch variation, protocol inconsistencies, sample degradation, or biological expression variability of TMEM178B. Use the same antibody lot for related experiments, standardize all protocol steps and reagents, use fresh samples with consistent preparation methods, and carefully control experimental conditions that may affect TMEM178B expression. Systematic troubleshooting following these guidelines will help overcome technical challenges when working with TMEM178B antibodies.